RecruitingPhase 3NCT05476939
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Studying Diffuse intrinsic pontine glioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Principal Investigator
- Jacques GRILL, MD, PhDGustave Roussy, Cancer Campus, Grand Paris
- Intervention
- Everolimus(drug)
- Enrollment
- 433 enrolled
- Eligibility
- All sexes
- Timeline
- 2022 – 2031
Study locations (30)
- Aarhus Universitetshospital Skejby, Aarhus, Denmark
- Rigshospitalet, Copenhagen, Denmark
- H.C. Andersen Children's Hospital, Odense Universitetshospital, Odense, Denmark
- Gustave Roussy, Villejuif, Val de Marne, France
- CHU d'Amiens-Picardie Site Sud, Amiens, France
- Institut de Cancérologie de l'Ouest (ICO) - Site Paul Papin, Angers, France
- CHU d'Angers - Bâtiment Robert Debré, Angers, France
- CHU Besançon - Hôpital Jean Minjoz, Besançon, France
- CHU de Bordeaux - Groupe hospitalier Saint André - Hôpital Saint André, Bordeaux, France
- CHU de Bordeaux - Groupe hospitalier Pellegrin - Hôpital des enfants, Bordeaux, France
- CHRU de Brest - Hôpital Morvan, Brest, France
- CHU de Caen - Hôpital Côte de Nacre, Caen, France
- CHU Estaing, Clermont-Ferrand, France
- Centre Jean Perrin, Clermont-Ferrand, France
- CHU François Mitterrand, Dijon, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Innovative Therapies For Children with Cancer Consortium · Ministry of Health, France · Jazz Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05476939 on ClinicalTrials.govOther trials for Diffuse intrinsic pontine glioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07076498Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care RadiationM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07501156H3K27M-specific Immune Effector Cells Targeting DMG/DIPGShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06838676ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasNationwide Children's Hospital
- RECRUITINGPHASE1NCT06305910CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsOX2 Therapeutics
- RECRUITINGPHASE1NCT06221553Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPGChulalongkorn University
- RECRUITINGPHASE1NCT05544526CAR T Cells to Target GD2 for DMGUniversity College, London
- RECRUITINGPHASE1NCT05762419FUS Etoposide for DMGColumbia University
- ACTIVE NOT RECRUITINGPHASE1NCT05768880Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System TumorsSeattle Children's Hospital